GAMMAGARD S/D IMMUNE GLOBULIN I.V. 2.5 G

Nazione: Israele

Lingua: inglese

Fonte: Ministry of Health

Principio attivo:

IMMUNOGLOBULIN NORMAL HUMAN 50 MG/ML

Commercializzato da:

TEVA MEDICAL MARKETING LTD.

Codice ATC:

J06BA02

Forma farmaceutica:

POWDER FOR SOLUTION FOR INJECTION

Via di somministrazione:

I.V

Prodotto da:

BAXTER HEALTHCARE CORPORATION, USA

Gruppo terapeutico:

IMMUNOGLOBULINS, NORMAL HUMAN, FOR INTRAVASCULAR ADM.

Indicazioni terapeutiche:

Replacement therapy in:• primary immunodeficiency syndromes (PID) such as: - congenital agammaglobulinaemia and hypogammaglobulinaemia; - common variable immunodeficiency; - severe combined immunodeficiency; - Wiskott Aldrich syndrome.• myeloma or chronic lymphocytic leukaemia (CLL) with severe secondary hypogammaglobulinaemia and recurrent infections.• children with congenital AIDS and recurrent infections.Immunomodulation• idiopathic thrombocytopenic purpura (ITP), in children or adults at high risk of bleeding or prior to surgery to correct the platelet count.• Guillain Barr? syndrome. In this case GAMMAGARD S/D (Solvent/Detergent) is only indicated in patients showing one of the following symptoms: - progressive paresis (the patient cannot walk more than 10 m on his own); - signs of a respiratory disorder (clinically observed or demonstrated by measuring the vital capacity at the patient’s bed); - signs of oropharyngeal paresis.• Kawasaki disease.Allogeneic bone marrow transplantation

Data dell'autorizzazione:

2010-07-01